Charles Schwab Investment Management Inc Aprea Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 16, 2021	SELL	$3.43 - $5.63 $172,755 - $283,560	-50,366 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.05 - $5.5 $73,689 - $100,072	-18,195 Reduced 26.54%	50,366 $246,000
Q1 2021 May 17, 2021	SELL	$4.73 - $8.15 $16,134 - $27,799	-3,411 Reduced 4.74%	68,561 $350,000
Q4 2020 Feb 16, 2021	BUY	$4.92 - $30.67 $6,022 - $37,540	1,224 Added 1.73%	71,972 $355,000
Q3 2020 Nov 13, 2020	BUY	$21.66 - $38.86 $598,119 - $1.07 Million	27,614 Added 64.02%	70,748 $1.7 Million
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $106,795 - $166,420	4,193 Added 10.77%	43,134 $1.67 Million
Q1 2020 May 15, 2020	BUY	$31.65 - $45.3 $14,843 - $21,245	469 Added 1.22%	38,941 $1.35 Million
Q4 2019 Feb 07, 2020	BUY	$18.94 - $49.53 $728,659 - $1.91 Million	38,472 New	38,472 $1.77 Million

Others Institutions Holding APRE

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.